Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05608252 · ClinicalTrials.gov registry record · Phase 1
VS-6766+Abema+Fulv in Met HR+/HER- BC
A Phase 1 study of Breast Cancer and Hormone Receptor-Positive Breast Cancer, sponsored by Adrienne G. Waks.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
- 3
- Study locations
NCT05608252: Recruiting Phase 1 study of Breast Cancer and Hormone Receptor-Positive Breast Cancer, sponsored by Adrienne G. Waks.
NCT05608252 is a Phase 1 study of Breast Cancer and Hormone Receptor-Positive Breast Cancer that is actively recruiting participants, run by Adrienne G. Waks. The registered enrollment target is 63 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05608252, a Phase 1 study of Breast Cancer and Hormone Receptor-Positive Breast Cancer, is actively recruiting participants, sponsored by Adrienne G. Waks.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer. The names of the study drugs involved in this study are: * VS-6766 * Abemaciclib * Fulvestrant
Primary Outcome
Determine maximum tolerated dose (MTD) of VS-6766 in combination with abemaciclib and fulvestrant using Bayesian Optimal Interval Design
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG VS-6766
- DRUG Abemaciclib
Study Locations (3)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institite - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2023-02-23 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
What NCT05608252 shows while recruiting
NCT05608252 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Fulvestrant is the first listed.
NCT05608252 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05608252 about?
NCT05608252 is a clinical study titled "VS-6766+Abema+Fulv in Met HR+/HER- BC". This research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer. The names of the study drugs involved in this study are: * VS-6766 * Abemaciclib * Fulvestrant
What is the current status of trial NCT05608252?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2023-02-23. Estimated completion is 2028-12-31.
What conditions does trial NCT05608252 study?
This clinical trial studies the following conditions: Breast Cancer, Hormone Receptor-Positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer.
What interventions are being tested in trial NCT05608252?
The interventions under investigation include: Fulvestrant (DRUG), VS-6766 (DRUG), Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT05608252?
This trial is sponsored by Adrienne G. Waks, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05608252 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05608252's enrollment target sits among peer trials
63 727th of 1224 higher than 495 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI